Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen-Cilag International
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
LYM3002 : Essai de phase 3, randomisé, évaluant l’efficacité de deux schémas thérapeutiques, VcR-CAP ou R-CHOP comprenant rituximab, cyclophosphamide, doxorubicine, prednisone associés au bortézomib ou à la vincristine respectivement, chez des patients ayant un lymphome à cellules du manteau. [essai clos aux inclusions]
L’objectif de cet essai est de déterminer l’association thérapeutique la plus efficace parmi deux schémas, VcR-CAP ou R-CHOP, chez des patients ayant un lymphome à cellules du manteau nouvellement dia...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Subjects With Premature Ejaculation
To demonstrate that dapoxetine (30 or 60 mg prn) can prolong intravaginal ejaculatory latency time (IELT) as measured by stopwatch when compared to placebo in men with PE during the 24-week treatment ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Update Il y a 4 ans
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects
To investigate mean changes in Hepatic Triglyceride Content (HTGC) from baseline to week 6 and 12 by 1H-Magnetic Resonance Spectroscopy (MRS) in obese subjects treated with JNJ-16269110: 10 mg bid, 1...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Proof-of Concept Study to Separately Study Talacotuzumab or Daratumumab in Low-Risk Intermediate-1 Risk Myelodysplastic Syndromes (MDS) patients
The primary objective of the study is to evaluate the efficacy (transfusion independence [TI]) of talacotuzumab (JNJ-56022473) or daratumumab in transfusion-dependent subjects with low or intermediate...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients with Schizophrenia
The primary objective of this study is to evaluate the efficacy of PP3M compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy
Establish the objective tumor response rate (CR + PR) following treatment with VELCADE plus Alimta or Alimta alone or VELCADE alone in subjects with locally advanced or metastatic NSCLC who have faile...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis Badanie służące ocenie leku Toreforant (JNJ-38518168) w leczeniu pacjentów z umiarkowaną do ciężkiej łuszczycą plackowatą”
To evaluate the efficacy of JNJ-38518168 in subjects with moderate to severe plaque-type psoriasis. To assess the safety and tolerability of JNJ-38518168 in subjects with moderate to severe plaque-ty...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International
Update Il y a 4 ans
A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral therapy-naïve HIV-1 infected subjects
To compare the proportion of subjects with at least one treatment-emergent Grade 1-4 CNS or psychiatric adverse event, observed between Baseline through Week 12 and judged by the investigator to be at...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
To compare the OS after treatment with trabectedin+DOXIL combination therapy to that observed after treatment with DOXIL monotherapy for subjects with platinum-sensitive advanced-relapsed epithelial o...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiety in Healthy Subjects
To determine whether R317573, after multiple dosing over one week in healthy male or female subjects, reduces the intensity of anxiety symptoms induced by breathing air with 7.5% carbon dioxide (CO2) ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next